FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379330365> ?p ?o ?g. }

• W4379330365 endingPage "5502" @default.
• W4379330365 startingPage "5502" @default.
• W4379330365 abstract "5502 Background: Definitive cisplatin-based chemoradiation (CRT) plus brachytherapy for locally advanced cervical cancer (FIGO IB3-IVA) results in sustained survival for 60-70% of patients. Recent studies integrating anti-PD-1 checkpoint immunotherapy (CALLA, NCT03830866) or consolidation chemotherapy (OUTBACK, ACTRN12610000732088) have not demonstrated a survival benefit over CRT. Intrinsic overexpression of ribonucleotide reductase may enhance DNA damage repair due to CRT. We report on the efficacy and tolerability of adding the ribonucleotide reductase inhibitor, triapine, to CRT. Methods: NRG GY006 is a randomized, open-label phase III clinical trial. Eligible patients had FIGO 2009 locally advanced cervical (stages IB2, II, IIIB or IVA without radiographic evidence of para-aortic nodal involvement) or stages II-IV vaginal cancer. Patients were randomly assigned to receive cisplatin (40 mg/m 2 weekly) with RT 45 Gy + lymph node boost alone (CRT) or CRT in combination with 15 total infusions of triapine (25 mg/m 2 IV) Mon/Wed/Fri (CRT + T). Both image guided IMRT or 3D RT were allowed but needed to be specified and pass a rigorous credentialing process. All RT plans had a pre-treatment review with expert planning feedback to the sites. The primary endpoint was overall survival (OS); secondary endpoint was progression-free survival. Exploratory endpoints included rate of complete metabolic response on post treatment PET/CT imaging at 3 months and knowledge-based planning for image guided IMRT. The target sample was 450 with 127 OS events. The design was to provide 80% power to detect a 10% improvement in OS at 3 years over the control (or HR = 0.6) at 2.5% significance level including one interim futility analysis at 50% information time. Results: Between 1/15/16 and 9/22/22 448 eligible patients were randomized to CRT (n=224) or CRT+T (n=224). The database was locked on 10/18/22 with 69 deaths. Median age was 47 years (range 23-85 years). The majority had cervical cancer (93.3%) and squamous cell carcinoma (82%). 52% had FIGO stage II disease. Racial/ethnic distribution included non-Hispanic white (53.8%), Hispanic/Latina (22.5%), and black (15.2%). IMRT was used in (74.3%) and HDR brachytherapy (98.2%) of cases. No differences in Grade 3-5 toxicities were observed: CRT =52% and CRT +T= 49% with Two G5 toxicities (cardiac arrest and acidosis) in the CRT+T arm. 343 patients have completed all protocol directed therapy. With a median follow-up of 28 months (IQR 15-45 months), the median PFS and OS for both arms were not reached yet. HR for death was 1.018 (95% CI 0.634-1.635), the conditional power was 15% to detect a HR = 0.6 at 100% information time. Conclusions: The addition of triapine to CRT did not improve OS. Clinical trial information: NCT02466971 ." @default.
• W4379330365 created "2023-06-05" @default.
• W4379330365 creator A5006402876 @default.
• W4379330365 creator A5011635381 @default.
• W4379330365 creator A5014611244 @default.
• W4379330365 creator A5020389827 @default.
• W4379330365 creator A5026671964 @default.
• W4379330365 creator A5027975591 @default.
• W4379330365 creator A5033923828 @default.
• W4379330365 creator A5043625183 @default.
• W4379330365 creator A5044870790 @default.
• W4379330365 creator A5045431626 @default.
• W4379330365 creator A5049011165 @default.
• W4379330365 creator A5049940232 @default.
• W4379330365 creator A5050839613 @default.
• W4379330365 creator A5053939897 @default.
• W4379330365 creator A5053990407 @default.
• W4379330365 creator A5054602117 @default.
• W4379330365 creator A5067271290 @default.
• W4379330365 creator A5087302565 @default.
• W4379330365 creator A5091030588 @default.
• W4379330365 creator A5092084825 @default.
• W4379330365 date "2023-06-01" @default.
• W4379330365 modified "2023-09-30" @default.
• W4379330365 title "Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial." @default.
• W4379330365 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.5502" @default.
• W4379330365 hasPublicationYear "2023" @default.
• W4379330365 type Work @default.
• W4379330365 citedByCount "0" @default.
• W4379330365 crossrefType "journal-article" @default.
• W4379330365 hasAuthorship W4379330365A5006402876 @default.
• W4379330365 hasAuthorship W4379330365A5011635381 @default.
• W4379330365 hasAuthorship W4379330365A5014611244 @default.
• W4379330365 hasAuthorship W4379330365A5020389827 @default.
• W4379330365 hasAuthorship W4379330365A5026671964 @default.
• W4379330365 hasAuthorship W4379330365A5027975591 @default.
• W4379330365 hasAuthorship W4379330365A5033923828 @default.
• W4379330365 hasAuthorship W4379330365A5043625183 @default.
• W4379330365 hasAuthorship W4379330365A5044870790 @default.
• W4379330365 hasAuthorship W4379330365A5045431626 @default.
• W4379330365 hasAuthorship W4379330365A5049011165 @default.
• W4379330365 hasAuthorship W4379330365A5049940232 @default.
• W4379330365 hasAuthorship W4379330365A5050839613 @default.
• W4379330365 hasAuthorship W4379330365A5053939897 @default.
• W4379330365 hasAuthorship W4379330365A5053990407 @default.
• W4379330365 hasAuthorship W4379330365A5054602117 @default.
• W4379330365 hasAuthorship W4379330365A5067271290 @default.
• W4379330365 hasAuthorship W4379330365A5087302565 @default.
• W4379330365 hasAuthorship W4379330365A5091030588 @default.
• W4379330365 hasAuthorship W4379330365A5092084825 @default.
• W4379330365 hasConcept C104292427 @default.
• W4379330365 hasConcept C104317684 @default.
• W4379330365 hasConcept C121608353 @default.
• W4379330365 hasConcept C126322002 @default.
• W4379330365 hasConcept C126894567 @default.
• W4379330365 hasConcept C143998085 @default.
• W4379330365 hasConcept C168563851 @default.
• W4379330365 hasConcept C185592680 @default.
• W4379330365 hasConcept C197934379 @default.
• W4379330365 hasConcept C203092338 @default.
• W4379330365 hasConcept C2776694085 @default.
• W4379330365 hasConcept C2777416452 @default.
• W4379330365 hasConcept C2778220009 @default.
• W4379330365 hasConcept C2778239845 @default.
• W4379330365 hasConcept C2778375690 @default.
• W4379330365 hasConcept C2989005 @default.
• W4379330365 hasConcept C4710235 @default.
• W4379330365 hasConcept C509974204 @default.
• W4379330365 hasConcept C55493867 @default.
• W4379330365 hasConcept C61943457 @default.
• W4379330365 hasConcept C71924100 @default.
• W4379330365 hasConceptScore W4379330365C104292427 @default.
• W4379330365 hasConceptScore W4379330365C104317684 @default.
• W4379330365 hasConceptScore W4379330365C121608353 @default.
• W4379330365 hasConceptScore W4379330365C126322002 @default.
• W4379330365 hasConceptScore W4379330365C126894567 @default.
• W4379330365 hasConceptScore W4379330365C143998085 @default.
• W4379330365 hasConceptScore W4379330365C168563851 @default.
• W4379330365 hasConceptScore W4379330365C185592680 @default.
• W4379330365 hasConceptScore W4379330365C197934379 @default.
• W4379330365 hasConceptScore W4379330365C203092338 @default.
• W4379330365 hasConceptScore W4379330365C2776694085 @default.
• W4379330365 hasConceptScore W4379330365C2777416452 @default.
• W4379330365 hasConceptScore W4379330365C2778220009 @default.
• W4379330365 hasConceptScore W4379330365C2778239845 @default.
• W4379330365 hasConceptScore W4379330365C2778375690 @default.
• W4379330365 hasConceptScore W4379330365C2989005 @default.
• W4379330365 hasConceptScore W4379330365C4710235 @default.
• W4379330365 hasConceptScore W4379330365C509974204 @default.
• W4379330365 hasConceptScore W4379330365C55493867 @default.
• W4379330365 hasConceptScore W4379330365C61943457 @default.
• W4379330365 hasConceptScore W4379330365C71924100 @default.
• W4379330365 hasFunder F4320332161 @default.
• W4379330365 hasIssue "16_suppl" @default.
• W4379330365 hasLocation W43793303651 @default.
• W4379330365 hasOpenAccess W4379330365 @default.
• W4379330365 hasPrimaryLocation W43793303651 @default.
• W4379330365 hasRelatedWork W1966946680 @default.

• next